Rapid Heme Panel

The Dana-Farber Cancer Institute and the Brigham and Women's Cancer Center have a launched Rapid Heme Panel, a next-gen sequencing-based panel that analyzes alterations in 95 genes that are frequently associated with leukemias and myeloid disorders. The test has a turnaround time of five business days.